2+ hour, 30+ min ago   (312+ words) ADVI's Tyler Seville on how the IRA's drug pricing provisions are creating compliance burdens manufacturers can't meet without data they don't have. In June of this year, Pharmaceutical Executive reported on Eli Lilly’s efforts to cut off 340B discounts to hospitals…...

1+ mon, 3+ week ago   (863+ words) As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel question: can "Healthcare Stewardship Capital" reconcile investor returns with patient welfare? The debate over private equity's role in healthcare has…...

2+ mon, 1+ week ago   (561+ words) Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating a months-long standoff with the American Hospital Association and prompting calls for federal intervention. Eli Lilly moved to cut off 340B Drug Pricing…...

3+ mon, 1+ week ago   (392+ words) A report from American Society of Health-System Pharmacists projects U.S. prescription drug spending to surpass $1T in 2026, driven largely by surging demand for GLP-1 weight-loss therapies. U.S. prescription drug spending is on track to surpass $1 trillion for the first time in 2026. Emerging Pharma…...

3+ mon, 2+ week ago   (557+ words) Regeneron announces agreement with the U.S. Government to set drug prices similarly to foreign prices, along with providing a new gene therapy free to eligible U.S. patients. Regeneron reached an agreement with the U.S. government to link current and future drug prices to…...

3+ mon, 4+ week ago   (414+ words) A more dynamic, data-driven approach is redefining what “good” looks like in copay support. Emerging Pharma Leaders nominations are now open! Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change…...

4+ mon, 1+ week ago   (452+ words) Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain. Emerging Pharma Leaders nominations are now open! Do you know someone who can make tough decisions that continue to face manufacturers?...

4+ mon, 1+ week ago   (119+ words) In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under Section 232, with significant carve-outs for companies that have struck MFN pricing deals or committed to domestic manufacturing, Pfizer and BioNTech halt a…...

4+ mon, 1+ week ago   (304+ words) Pharmaceutical companies that made MFN deals with the Trump administration will be exempt from the tariffs, along with other exemptions. After months of threats, President Trump issued major tariffs on pharmaceutical products. The tariffs will do into effect in 120 days…...

4+ mon, 3+ week ago   (504+ words) In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two biotech companies focused on next-generation T-cell engager therapies…...